Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a response rate of 26% and a median overall survival of 9 months.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2019-10, Vol.381 (17), p.1632-1643
Hauptverfasser:	Kopetz, Scott, Grothey, Axel, Yaeger, Rona, Van Cutsem, Eric, Desai, Jayesh, Yoshino, Takayuki, Wasan, Harpreet, Ciardiello, Fortunato, Loupakis, Fotios, Hong, Yong Sang, Steeghs, Neeltje, Guren, Tormod K, Arkenau, Hendrik-Tobias, Garcia-Alfonso, Pilar, Pfeiffer, Per, Orlov, Sergey, Lonardi, Sara, Elez, Elena, Kim, Tae-Won, Schellens, Jan H.M, Guo, Christina, Krishnan, Asha, Dekervel, Jeroen, Morris, Van, Calvo Ferrandiz, Aitana, Tarpgaard, L.S, Braun, Michael, Gollerkeri, Ashwin, Keir, Christopher, Maharry, Kati, Pickard, Michael, Christy-Bittel, Janna, Anderson, Lisa, Sandor, Victor, Tabernero, Josep
Format:	Artikel
Sprache:	eng
Schlagworte:	5-Fluorouracil Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzimidazoles - administration & dosage Biotechnology Cancer Cancer therapies Carbamates - administration & dosage Cetuximab - administration & dosage Clinical trials Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Disease Progression Electrocorticography Epidermal growth factor Female Folinic acid Humans Immunotherapy Intention to Treat Analysis Irinotecan Irinotecan - therapeutic use Kaplan-Meier Estimate Kinases Male Medical prognosis Metastases Metastasis Middle Aged Monoclonal antibodies Mutation Oncology Pharmaceuticals Pharmacology Proto-Oncogene Proteins B-raf - genetics Response rates Sulfonamides - administration & dosage Survival Survival Analysis Targeted cancer therapy Technical communication
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a response rate of 26% and a median overall survival of 9 months.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa1908075